Ten Key Developments in Cancer Research

From immunotherapy and personalized treatments to CRIPSR and antibody drug conjugates, the world of cancer research is rapidly advancing in exciting ways

According to Cancer Research UK, one in two people will be diagnosed with cancer during their lifetime, and one in three will die with the disease. The World Health Organization reports that approximately 10 million people die from cancer each year globally. The number of new cancer cases is projected to increase by 75% between now and 2050. While cancer can develop in any part of the body, the most common types are breast, lung, colorectal (colon and rectum), and prostate cancer. Around one-third of all cancers can be prevented through lifestyle changes, such as managing obesity, exercising regularly, not smoking, and limiting alcohol consumption.

Despite these alarming figures, there is more hope than ever for those at risk of cancer and those currently battling the disease. Half of all cancer patients now survive for 10 years or more. Advances in early diagnosis are leading to improved outcomes, and ongoing developments in diagnostics, treatments, and preventive measures offer hope for a brighter future. Some of the most exciting developments are:

1. Immunotherapy

Immunotherapy has revolutionized cancer treatment by harnessing the body’s immune system to fight cancer. Key advancements include:

• Checkpoint inhibitors (e.g., pembrolizumab, nivolumab): These drugs block proteins that cancer cells use to evade the immune system, allowing T-cells to target and destroy cancer cells. We are now seeing combinations of checkpoint inhibitors with other drugs, including bispecifics, playing an important role in fighting cancer.
• CAR-T cell therapy: Chimeric Antigen Receptor T-cell therapy involves modifying a patient’s T-cells to better recognize and attack cancer cells. This has been particularly effective in blood cancers like leukemia and lymphoma.

2. Antibody drug conjugates

Antibody-drug conjugates (ADCs) represent a powerful class of targeted cancer therapies that utilize the precision of monoclonal antibodies to deliver cytotoxic payloads directly to tumor cells, minimizing the risk of off-target toxicity and reducing adverse events compared to conventional chemotherapy. Payload classes include microtubule targeting, DNA damaging, RNA polymerase damaging and spliceosomal inhibition.

3. Personalized Medicine

Personalized or precision medicine uses genetic and molecular information from an individual’s cancer to tailor treatments specifically to the patient’s disease profile. Advances in genomics and biomarker identification allow for more precise treatments that maximize efficacy while minimizing unnecessary side effects. This includes testing tumors for genetic mutations and using this data to choose the most effective therapies.

4. Artificial Intelligence (AI) and Machine Learning

AI is being increasingly used in both diagnosis and treatment planning. AI algorithms can analyze medical imaging (like CT scans, MRIs, and pathology slides) to detect cancer earlier and with greater accuracy. In addition, AI is helping to identify patterns in data that can lead to the development of new treatments and better patient management strategies.

5. Cancer Vaccines

Vaccines are being developed to prevent and treat cancer. The first FDA-approved cancer vaccine, the HPV vaccine, helps prevent cancers caused by the human papillomavirus. Additionally, therapeutic cancer vaccines are being explored to help the immune system recognize and attack cancer cells. These vaccines are still in clinical trials but offer promising potential for future cancer treatments.

6. CRISPR and Gene Editing

CRISPR technology allows for precise editing of genes, which could be used to directly correct cancer-causing mutations or enhance the immune system’s ability to fight cancer. Research into CRISPR for cancer treatment is still in early stages, but it holds the potential for groundbreaking, personalized cancer therapies.

7. Oncolytic Virus Therapy

Oncolytic virus therapy uses genetically modified viruses to selectively infect and destroy cancer cells. These viruses can also stimulate the immune system to target and attack remaining cancer cells. Trials are ongoing for various cancers, including melanoma and glioblastoma, showing promising potential.

8. Neoantigen-Based Therapy

Neoantigens are unique proteins found on the surface of cancer cells, resulting from genetic mutations in the tumor. Targeting these neoantigens is an exciting approach for developing cancer vaccines and personalized treatments. Clinical trials are exploring how to use these neoantigens to stimulate the immune system to recognize and kill cancer cells.

9. Advanced Radiation Therapy (Proton and Heavy Ion Therapy)

Proton therapy and heavy ion therapy are advanced forms of radiation therapy that use charged particles instead of X-rays to treat cancer. These therapies are more precise, minimizing damage to surrounding healthy tissue, and are particularly beneficial for treating tumors near critical structures or in pediatric patients.

10. Organoids and 3D Cell Culture Models

Organoids are 3D cell cultures that mimic the structure and function of human organs, providing a more accurate model of cancer biology. These models are being used to evaluate new drugs and personalize treatments for patients, allowing for better predictions of how a tumor will respond to specific therapies.

These advances are significantly improving the accuracy of diagnoses, expanding treatment options, and providing patients with therapies that are more personalized, effective, and less invasive. As these technologies continue to develop, the landscape of cancer treatment and management will continue to evolve, offering hope for better outcomes and even potential cures in the future.

Justin Bryans joined Charles River in April 2022 as Chief Scientific Officer (Discovery) where he works closely with the leadership and Science Directors to explore opportunities with existing and prospective clients and evaluate new areas of science and new approaches to strengthen the Charles River offering. He has a particular interest in the interface of small molecule and biologics and the use of big data, informatics, and AI to speed up the drug discovery process, reduce clinical attrition, and deliver quality drugs to patients. Justin and the Science Director team help others in Charles River by providing a wide range of expertise and knowledge to help deliver transformative new therapies.